Trade Filings
Gestori Titoli Depositi Superinvestor
Segnali Acquisti istituzionali Vendite istituzionali Attività insider 13D & 13G Watch Rotazione settoriale
Strumenti Screener azionario Screener gestori Confronta gestori Consensus Baskets Tutti gli strumenti di ricerca API dati
Approfondimenti & AI Approfondire Chiedi ai dati Agenti AI
Notizie ★ Salvato
Informazioni Chi siamo Metodologia Contatti Disclaimer
Reader
PIANI DATI

Download di dati storici — disponibili con gli account.

API GATEWAY

Accesso JSON in sola lettura ai dati in cache del sito.

Modalità scura

🧭 Vista guidata
Nuovo sui mercati — prezzi, rendimenti, YTD, capitalizzazione di mercato? Spieghiamo ogni termine durante la navigazione, in linguaggio chiaro. Gli stessi dati, con il supporto integrato.

⚡ Parere esperto
Conosci già il mercato. Solo i dati — puliti, veloci e compatti, senza spiegazioni aggiuntive. Questa è la visualizzazione predefinita.

Lingua dell'interfaccia
Scheda del titolo

LLY

Eli Lilly and Company · Healthcare · Drug Manufacturers - General

1,233.5 -1.1% cap. di mercato $1.16T quotazione ritardata (FMP) · al Aug 25 22:08 UTC — separato dai dati del deposito di seguito

Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024
193Holder monitorati
+4Δ titolari
671.92MQuote detenute
$804.91BValore dichiarato
+6Nuove posizioni
−1Uscite
Stable Punteggio di convinzione 48/100 Come vengono calcolati → Approfondisci al Research Desk →

Input di momentum (manager comparabili): ampiezza dei detentori +2.1% · flusso azionario -0.1% · nuove posizioni nette +2.6%formula
Frammentazione della proprietà — più detentori, quota aggregata minore

Tutte le cifre di proprietà: solo gestori 13F monitorati, posizioni in azioni ordinarie, periodo di riferimento Q2 2026

Proprietà nel tempo
TrimestreDetentoriΔQuoteValore dichiaratoNuovoUscite
Q2 2026 193 +4 671.92M $804.91B +6 −1
Q1 2026 191 -3 666.59M $613.20B +1 −5
Q4 2025 193 +2 707.04M $758.81B +3
Q3 2025 27 -3 329.88M $251.63B +2 −6
Q2 2025 28 -1 307.45M $239.60B +2 −3
Q1 2025 26 0 140.32M $115.83B +1 −1
Q4 2024 26 +1 145.00M $111.91B +3 −2
Q3 2024 24 +2 109.89M $97.29B +2
Q2 2024 22 112.43M $101.75B
Numero di detentori
Chi lo detiene · Q2 2026
#GestoreQuoteΔ azioniValoreIl loro pesoDetenuto
1 Lilly Endowment Inc 90.38M -1.6% $108.40B 100.0% ▼ Trim 3 SEC ↗
2 BlackRock (passivo) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
3 BlackRock (passivo) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
4 BlackRock (passivo) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
5 BlackRock (passivo) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
6 BlackRock (passivo) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
7 BlackRock (passivo) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
8 BlackRock (passivo) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
9 BlackRock (passivo) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
10 BlackRock (passivo) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
11 BlackRock (passivo) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
12 BlackRock (passivo) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
13 BlackRock (passivo) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
14 BlackRock (passivo) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
15 BlackRock (passivo) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
16 BlackRock (passivo) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
17 BlackRock (passivo) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
18 BlackRock (passivo) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
19 BlackRock (passivo) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
20 BlackRock (passivo) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
21 BlackRock (passivo) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
22 BlackRock (passivo) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
23 BlackRock (passivo) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
24 BlackRock (passivo) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
25 Vanguard Capital Management Llc 53.53M +0.3% $64.20B 1.4% ▲ Add 2 SEC ↗
26 Pnc Financial Services Group, Inc. 51.32M 0.0% $61.56B 30.5% ▼ Trim 3 SEC ↗
27 Pnc Financial Services Group, Inc. 51.32M 0.0% $61.56B 30.5% ▼ Trim 3 SEC ↗
28 Pnc Financial Services Group, Inc. 51.32M 0.0% $61.56B 30.5% ▼ Trim 3 SEC ↗
29 Pnc Financial Services Group, Inc. 51.32M 0.0% $61.56B 30.5% ▼ Trim 3 SEC ↗
30 Pnc Financial Services Group, Inc. 51.32M 0.0% $61.56B 30.5% ▼ Trim 3 SEC ↗
31 Pnc Financial Services Group, Inc. 51.32M 0.0% $61.56B 30.5% ▼ Trim 3 SEC ↗
32 Pnc Financial Services Group, Inc. 51.32M 0.0% $61.56B 30.5% ▼ Trim 3 SEC ↗
33 Pnc Financial Services Group, Inc. 51.32M 0.0% $61.56B 30.5% ▼ Trim 3 SEC ↗
34 Pnc Financial Services Group, Inc. 51.32M 0.0% $61.56B 30.5% ▼ Trim 3 SEC ↗
35 Pnc Financial Services Group, Inc. 51.32M 0.0% $61.56B 30.5% ▼ Trim 3 SEC ↗
36 Pnc Financial Services Group, Inc. 51.32M 0.0% $61.56B 30.5% ▼ Trim 3 SEC ↗
37 State Street Global Advisors (passivo) 36.22M +1.7% $43.44B 1.3% ▲ Add 7 SEC ↗
38 Fidelity (FMR) 28.46M +8.1% $34.14B 1.5% ▲ Add 5 SEC ↗
39 Fidelity (FMR) 28.46M +8.1% $34.14B 1.5% ▲ Add 5 SEC ↗
40 Fidelity (FMR) 28.46M +8.1% $34.14B 1.5% ▲ Add 5 SEC ↗
41 Fidelity (FMR) 28.46M +8.1% $34.14B 1.5% ▲ Add 5 SEC ↗
42 Fidelity (FMR) 28.46M +8.1% $34.14B 1.5% ▲ Add 5 SEC ↗
43 Fidelity (FMR) 28.46M +8.1% $34.14B 1.5% ▲ Add 5 SEC ↗
44 Fidelity (FMR) 28.46M +8.1% $34.14B 1.5% ▲ Add 5 SEC ↗
45 Capital Research Global Investors 20.87M -15.3% $25.04B 3.5% ▼ Trim 3 SEC ↗
46 Geode Capital Management (passivo) 20.31M +0.6% $24.28B 1.3% ▲ Add 9 SEC ↗
47 Geode Capital Management (passivo) 20.31M +0.6% $24.28B 1.3% ▲ Add 9 SEC ↗
48 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
49 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
50 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
51 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
52 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
53 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
54 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
55 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
56 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
57 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
58 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
59 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
60 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
61 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
62 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
63 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
64 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
65 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
66 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
67 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
68 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
69 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
70 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
71 Capital World Investors 15.90M +1.8% $19.08B 2.3% ▲ Add 9 SEC ↗
72 T. Rowe Price 13.91M -0.6% $16.69B 1.7% ▼ Trim 9 SEC ↗
73 T. Rowe Price 13.91M -0.6% $16.69B 1.7% ▼ Trim 9 SEC ↗
74 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
75 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
76 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
77 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
78 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
79 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
80 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
81 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
82 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
83 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
84 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
85 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
86 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
87 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
88 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
89 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
90 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
91 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
92 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
93 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
94 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
95 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
96 Norges Bank (passivo) 11.47M Nuovo $13.76B 1.4% New 1 SEC ↗
97 Bank Of America Corp /De/ 11.27M +1.3% $13.52B 0.9% ▲ Add 3 SEC ↗
98 Bank Of America Corp /De/ 11.27M +1.3% $13.52B 0.9% ▲ Add 3 SEC ↗
99 Bank Of America Corp /De/ 11.27M +1.3% $13.52B 0.9% ▲ Add 3 SEC ↗
100 Bank Of America Corp /De/ 11.27M +1.3% $13.52B 0.9% ▲ Add 3 SEC ↗

"Il loro peso" = la quota della posizione sul valore azionario 13F dichiarato da quel gestore — la misura di convinzione. ✦ = gestore selezionato.

Nuovi acquirenti

Norges Bank $13.76B 1.4%

Uscito

Walleye Trading LLC $4.34M era 0.1%

Contesto di mercato completo: su TUTTI i filer 13F (dati strutturati SEC, Q1 2026): 4,323 detentori, 762.84M azioni, $674.93B dichiarato. Questo è un periodo diverso e più vecchio rispetto ai dati dell'universo monitorato riportati sopra e i due non vengono mai combinati.

Frequentemente co-detenuti

Cosa detengono più spesso gli altri holder monitorati di questo titolo — conteggi di proprietà condivisa, non relazioni fondamentali.

Transazioni insider

Acquisti sul mercato aperto (P)

Nessun acquisto insider sul mercato aperto nella nostra finestra di copertura.

Vendite sul mercato aperto (S)

Aug 17 Jonsson Patrik

Officer · 6.50K az. · $7.64M

Aug 10 Zakrowski Donald A

Officer · 2.00K az. · $2.37M

Aug 07 Hakim Anat

Officer · 5.00K az. · $5.95M

Assegnazioni, esercizi e ritenute fiscali non vengono mai conteggiati come acquisti o vendite in questa sede. Metodologia

Beneficial ownership
Jul 23 SC 13G/A — LILLY ENDOWMENT INC

Visualizza la dichiarazione SEC originale ↗

Nelle notizie
Aug 24 FDA Clears Roche And Eli Lilly's Alzheimer's Blood Test ↗

The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify…

Forbes
Aug 24 FDA Approves Alzheimer's Blood Test Developed by Roche and Eli Lilly ↗

The Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed…

WSJ
Aug 24 Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance ↗

The U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood test to help ​identify signs of…

Reuters
Aug 24 Eli Lilly Launches Foundayo Weight-Loss Pill in U.K. ↗

The once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event…

WSJ
Aug 23 Eli Lilly launches oral weight-loss pill Foundayo in UK ↗

Eli Lilly said on Monday it has launched its oral pill, ​Foundayo, in the UK for weight ‌management and type 2…

Reuters
Provenienza: Proprietà ricavata dalle posizioni in azioni ordinarie 13F analizzate (universo monitorato, set comparabili per le variazioni); righe insider dai Moduli 3/4/5; partecipazioni dagli Schedule 13D/13G; ogni filing rimanda all'originale su SEC EDGAR. Periodo di rendicontazione: Q2 2026 · Metodologia · Ottieni questo tramite l'API